Sagar Lonial
Independent DirectorDr. Sagar Lonial, M.D., FACP, Ph.D., an internationally recognized authority in multiple myeloma and lymphoma treatment and research. Dr. Lonial serves as Independent Director of TG Therapeutics Inc. since April 2020. He has been Chief Medical Officer at Winship Cancer Institute of Emory University since March 9, 2015. Dr. Lonial is the Editor of several leading peer-reviewed journals. He oversees all clinical care initiatives for both clinicians and patients. Dr. Lonial is professor and Executive Vice Chair of Emory's Department of Hematology and Medical Oncology. Dr. Lonial is a trained bone marrow transplant physician with an interest in molecular therapy for lymphoma and myeloma. Dr. Lonial is involved in numerous professional organizations including the American Society of Clinical Oncology, American Society of Hematology and the American Society for Blood and Marrow Transplantation, as well as involved in research with the Multiple Myeloma Research Foundation (MMRF), the Lymphoma Research Foundation (LRF) and the Leukemia and Lymphoma Society (LLS). Dr. Lonial has authored or coauthored over 200 peer-reviewed publications. He serves on the editorial board of the Journal of Clinical Oncology, Leukemia, is the myeloma editor for Clinical Lymphoma, Myeloma and Leukemia and is the hematologic malignancies section editor for the journal Cancer. His research focuses on combination therapy in B-cell malignancies focusing on myeloma. His previous laboratory work has focused on evaluating the impact of purified dendritic cell subsets on the nature of immune responses against antigen and he has completed several trials evaluating the impact of cytokines on dendritic cell content and post-transplant immune recovery. Most recently, Dr. Lonial has worked on combinations of novel agents as therapy for myeloma and lymphoma, particularly evaluating combinations that may result in synergistic inhibition of the PI3-K/Akt pathway. He served as Director of Emory Healthcare, Inc. He serves as Member of Managing Myeloma Advisory Board at MediCom Worldwide, Inc. He served as Member of Nox-A12 Advisory Board of NOXXON Pharma N.V. He serves as Member of Scientific Advisory Board of SkylineDx B.V. He has received the Celgene Young Investigator Award, Indo American Cancer Association Lifetime Achievement Award, the COMY Multiple Myeloma Excellence Award for Clinical Science and the Giants of Cancer Care inductee and holds the Anne and Bernard Gray Family Chair in Cancer. He earned his medical degree from the University of Louisville School of Medicine. He completed his internship and residency at Baylor College of Medicine in Houston, Texas, followed by a fellowship in hematology and oncology at Emory University School of Medicine in Atlanta, Georgia. Dr. Sagar Lonial is Member of Clinical Advisory Board of K36 Therapeutics, Inc. from November 2025.
Positions
- Company NameTG Therapeutics, Inc.Stock CodeTGTXPositionIndependent DirectorColleagues
- MSMichael S. WeissChairman, CEO & President
- SASean A. PowerCFO, Corporate Secretary & Treasurer
- JBJenna BoscoSenior Vice President of Corporate Communications
- AWAdam WaldmanChief Commercialization Officer
- LNLaurence N. CharneyLead Independent Director
- KHKenneth HobermanIndependent Director
- YEYann EchelardIndependent Director
